title: [Fixed drug eruption after taking ethambutol].
abstract: BACKGROUND
  Fixed drug eruption (FDE) is a specific skin reaction and the only exclusively medicinal dermatosis. Among the drugs usually responsible are the antituberculous antibiotics including rifampicin and, less often, isoniazid and pyrazinamide. FDE after taking ethambutol is rarely described.
  
  
  METHODS
  A 32-year old HIV negative patient presented a FDE localized to the internal surface of the lips and the interdigital folds during the 4th month of antituberculous treatment comprising rifampicin, isoniazid and ethambutol. The diagnosis was supported by the characteristic appearances of the lesions of FDE and their early reappearance in the same areas after accidental reintroduction of antituberculous triple therapy including ethambutol. Double-agent therapy with rifamicin and isoniazid was tolerated well.
  
  
  CONCLUSIONS
  Discovery of FDE requires a rigorous search for the responsible medicine. During antituberculous treatment, the practitioner has to bear in mind the potential role of ethambutol, which is possibly potentiated by rifampicin.
authors.affiliation: Service de pneumophtisiologie, CHU de Treichville, BP V 3, Abidjan, Côte d'Ivoire. Electronic address: sandia211@hotmail.com.
authors.forename: A S
authors.initials: AS
authors.lastname: Bakayoko
authors.affiliation: Service de dermatovénérologie, CHU de Treichville, Abidjan, Côte d'Ivoire.
authors.forename: M
authors.initials: M
authors.lastname: Kaloga
authors.affiliation: Service de pharmacologie clinique, CHU de Cocody, Abidjan, Côte d'Ivoire.
authors.forename: M
authors.initials: M
authors.lastname: Kamagate
authors.affiliation: Service de pneumophtisiologie, CHU de Treichville, BP V 3, Abidjan, Côte d'Ivoire.
authors.forename: Z
authors.initials: Z
authors.lastname: Kone
authors.affiliation: Service de pneumophtisiologie, CHU de Treichville, BP V 3, Abidjan, Côte d'Ivoire.
authors.forename: A T J
authors.initials: AT
authors.lastname: Daix
authors.affiliation: Service de pneumophtisiologie, CHU de Treichville, BP V 3, Abidjan, Côte d'Ivoire.
authors.forename: E
authors.initials: E
authors.lastname: Ohui
authors.affiliation: Service de dermatovénérologie, CHU de Treichville, Abidjan, Côte d'Ivoire.
authors.forename: I
authors.initials: I
authors.lastname: Gbery
authors.affiliation: Service de pneumophtisiologie, CHU de Treichville, BP V 3, Abidjan, Côte d'Ivoire.
authors.forename: K
authors.initials: K
authors.lastname: Domoua
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced; D007538:Isoniazid / Q000627:therapeutic use; D008047:Lip Diseases / Q000139:chemically induced; D008297:Male; D012293:Rifampin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications
chemical_list: D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
keywords: Adult; Adulte; Adverse effects; Antituberculeux; Antituberculous agents; Effets indésirables; Ethambutol; Fixed drug eruption; Érythème pigmenté fixe; Éthambutol